Nidhi Raval

Nidhi Raval

Auto-generated profile, based on publicly available information

Nidhi Raval

National Institute of Pharmaceutical Education and Research (NIPER)-Ahmedabad, Gandhinagar, Gujarat, India

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
DKDnyaneshwar Kalyane
Dnyaneshwar Kalyane
NRNidhi Raval
Nidhi Raval
RMRahul Maheshwari
Rahul Maheshwari
VTVishakha Tambe
Vishakha Tambe
KKKiran Kalia
Kiran Kalia
RTRakesh Kumar Tekade
Rakesh Kumar Tekade

1 January 2019
Verified
Book Chapter
Closed access
NRNidhi Raval
Nidhi Raval
RMRahul Maheshwari
Rahul Maheshwari
DKDnyaneshwar Kalyane
Dnyaneshwar Kalyane
SYSusanne R. Youngren-Ortiz
Susanne R. Youngren-Ortiz
MCMahavir B. Chougule
Mahavir B. Chougule
RTRakesh K. Tekade
Rakesh K. Tekade

1 January 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
VMVimalkumar Johnson Muniswamy
Vimalkumar Johnson Muniswamy
NRNidhi Raval
Nidhi Raval
PGPiyush Gondaliya
Piyush Gondaliya
VTVishakha Tambe
Vishakha Tambe
KKKiran Kalia
Kiran Kalia
RTRakesh Kumar Tekade
Rakesh Kumar Tekade

1 May 2019 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
PPPramina Kumari Pandey
Pramina Kumari Pandey
RMRahul Maheshwari
Rahul Maheshwari
NRNidhi Raval
Nidhi Raval
PGPiyush Gondaliya
Piyush Gondaliya
KKKiran Kalia
Kiran Kalia
RTRakesh Kumar Tekade
Rakesh Kumar Tekade

9 April 2018 in Nanoscale
Verified
Journal Article
Closed access
PDF file
KKKaushik Kuche
Kaushik Kuche
RMRahul Maheshwari
Rahul Maheshwari
VTVishakha Tambe
Vishakha Tambe
KMKit-Kay Mak
Kit-Kay Mak
HJHardi Jogi
Hardi Jogi
RTRakesh Kumar Tekade
Rakesh Kumar Tekade
The search for effective and non-invasive delivery modules to transport therapeutic molecules across skin has led to the discovery of a number of nanocarriers (viz.: liposomes, ethosomes, dendrimers, etc.) in the last few decades. However, available literature suggests that these delivery modules face several issues including poor stability, low encapsulation efficiency, and scale-up hurdles. Recently, carbon nanotubes (CNTs) emerged as a versatile tool to deliver therapeutics across skin. Superior stability, high loading capacity, well-developed synthesis protocol as well as ease of scale-up are some of the reason for growing interest in CNTs. CNTs have a unique physical architecture and a large surface area with unique surface chemistry that can be tailored for vivid biomedical applications. CNTs have been thus largely engaged in the development of transdermal systems such as tuneable hydrogels, programmable nonporous membranes, electroresponsive skin modalities, protein channel mimetic platforms, reverse iontophoresis, microneedles, and dermal buckypapers. In addition, CNTs were also employed in the development of RNA interference (RNAi) based therapeutics for correcting defective dermal genes. This review expounds the state-of-art synthesis methodologies, skin penetration mechanism, drug liberation profile, loading potential, characterization techniques, and transdermal applications along with a summary on patent/regulatory status and future scope of CNT based skin therapeutics.

2 January 2018 in Journal of Microencapsulation
Verified
Journal Article
Closed access
NRNidhi Raval
Nidhi Raval
Dignesh KhuntDignesh Khunt
Dignesh Khunt
MMmanju misra
manju misra
The aim of the study was to formulate a microemulsion (ME) using chitosan (CH) and the butter oil (BO) as a permeation enhancer for targeting drug to the posterior segment of the eye, via topical route. Triamcinolone acetonide (TA) was selected as the model drug since it undergoes extensive first-pass metabolism, leading to poor oral bioavailability of 23%. For optimisation of BO concentration, different ratios of TA:BO were prepared by simple physical mixing in the ratio of 1:9 to 9:1 and diffusion study was performed. MEs containing TA, TA:BO and TA CH ME were formulated by water titration method. Globule sizes of TA ME, TA:BO ME and TA CH ME were found to be 66.06 ± 0.32 nm, 78.52 ± 1.50 nm and 97.30 ± 2.50 nm, respectively. In ex vivo diffusion studies using goats eye, TA:BO ME (31.33 ± 0.46 and 33.98 ± 0.23) and TA CH ME (24.10 ± 0.41 and 27.00 ± 0.18) showed higher percentage of drug diffusion in comparison to TA ME (13.29 ± 0.41and 15.56 ± 0.34) and TA solution (8.20 ± 1.04 and 10.39 ± 0.22) in presence and in absence of vitreous humour. Fluorescence intensity of coumarin-6 (as a marker) loaded ME with BO and CH was found to be higher, confirming their role in altering membrane permeability and facilitating coumarin-6 diffusion to the posterior chamber. Overall, it was concluded that BO enhances the bioavailability of TA across the retina, thereby proving its potential as permeation enhancer in facilitating drug delivery to the posterior segment of the eye.